Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation (Occlusion-AF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03642509|
Recruitment Status : Recruiting
First Posted : August 22, 2018
Last Update Posted : January 5, 2021
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold. Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding. Moreover, 30% with AF and at risk of stroke are not in relevant anticoagulation. The randomized PROTECT-AF trial has demonstrated the superiority of left atrial appendage occlusion (LAAO) as compared to warfarin for prevention of the combined endpoint of stroke, major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with novel oral anticoagulants (NOAC) have not been carried out.
This study aims to assess the effect of left atrial appendage occlusion (LAAO) to reduce the incidence of stroke, systemic embolism, major bleeding and all-cause mortality in patients with atrial fibrillation (AF) and a prior ischemic stroke or transient ischemic attack (TIA).
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Stroke||Device: Left atrial appendage occlusion Drug: NOAC||Not Applicable|
An investigator-initiated multicenter, randomized open-label non-inferiority trial with blinded outcome evaluation (PROBE design). The active comparison LAAO is tested against NOAC therapy in a 1:1 stratified randomization. Patients should have AF, and an ischemic stroke or TIA within 6 months prior to enrollment. In total 750 patients will be included. Follow-up will be based on in-office and telephone follow-up during the first 3 years after randomization, along with up to 10 years long-term follow-up through the National Patient Registries.
The main study outcomes: The primary outcome is a composite of stroke (hemorrhagic or ischemic), systemic embolism, major bleeding or all-cause mortality assessed after at least two years follow-up for the last enrolled patient. Secondary outcomes will examine early and late safety outcome measures. The long-term outcome will be assessed up to 10-years after randomization through the National Patient Registries.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||750 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Open-label study with blinded outcome assessment by an independent clinical event committee|
|Official Title:||Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF)|
|Actual Study Start Date :||January 1, 2019|
|Estimated Primary Completion Date :||January 1, 2024|
|Estimated Study Completion Date :||October 1, 2030|
Experimental: LAAO group
Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
Device: Left atrial appendage occlusion
Interventional left atrial appendage occlusion with the Amulet or Watchman device
Other Name: Left atrial appendage closure
Experimental: NOAC group
Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
- Composite endpoint of stroke (ischemic and hemorrhagic), systemic embolism, major bleeding and all-cause mortality. [ Time Frame: Up to 5-years from randomization ]The primary endpoint is the combined rate of stroke, systemic embolism, major bleeding and all-cause mortality.
- Incidence of ischemic stroke [ Time Frame: 2-, 3-, 5- and 10-years ]The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as ischemic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.
- Incidence of hemorrhagic stroke [ Time Frame: 2-, 3-, 5- and 10-years ]The occurrence of an acute onset of a focal neurological deficit of presumed vascular origin lasting for ≥ 24 hours or resulting in death. Stroke is categorized as hemorrhagic based on computed tomography (CT) or magnetic resonance imaging (MRI) of the brain or autopsy.
- Incidence of systemic embolism [ Time Frame: 2-, 3-, 5- and 10-years ]The occurrence of an acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical or autopsy evidence of arterial occlusion in the absence of other likely mechanism (e.g. trauma, atherosclerosis, or instrumentation).
- Incidence of major or life-threatening bleeding [ Time Frame: 2-, 3-, 5- and 10-years ]The occurrence of an overt bleeding associated with one or more of the following: decrease in hemoglobin of at least 3.0 g/dL, transfusion of 2 or more units of blood, causing hospitalization, requiring surgery, causing discontinuation of all antithrombotic therapy or pericardial bleeding with/without tamponade or occurring during the index LAAO procedure or during hospitalization for the index procedure (major bleeding). Life-threatening bleeding is defined as fatal bleeding, causing hypovolaemic shock or severe hypotension requiring vasopressor therapy or intervention, symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, intramuscular with compartment syndrome, pericardial bleeding after hospitalization for the index LAAO) or overt bleeding with decrease in hemoglobin ≥ 5 g/dL or requiring transfusion of ≥ 4 units of blood.
- Incidence of all-cause mortality [ Time Frame: 2-, 3-, 5- and 10-years ]The occurrence of death from any cause
- Incidence of Transient ischemic attack (TIA) [ Time Frame: 2-, 3-, 5- and 10-years ]an episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia leading to symptoms lasting less than 24 hours, without acute infarction based on neuroimaging.
- Number of patients with a device-related complication [ Time Frame: 2 months ]
A complication related to the presence of the device. Device-related complications include:
- Device embolization
- Device erosion
- Clinically significant device interference with surrounding structures. This includes structures at the implant location (circumflex coronary artery, mitral valve, pulmonary artery, pulmonary vein) or cardiovascular structures in the vicinity of the location to which the device migrated (if applicable).
- Device thrombus
- Device fracture
- Device infection/endocarditis/pericarditis
- Device perforation/laceration
- Device allergy
- Number of patients with a procedure-related complication [ Time Frame: 2 months ]All complications related to the LAAO-procedure will be assessed.
- Number of patients with a device success [ Time Frame: 2 months ]Device deployed and implanted in correct position
- Number of patients with technical success [ Time Frame: 2 Months ]Exclusion of the left atrial appendage (LAA) achieved without device-related complications and no leak >5 mm on color Doppler TEE.
- Number of patients with procedural success [ Time Frame: 2 months ]Technical success and no procedure-related complications, except uncomplicated device embolization (i.e. device embolization resolved by percutaneous retrieval during the procedure without surgical intervention or damage to surrounding cardiovascular structures).
- Number of patients with peri-device leaks at follow-up imaging [ Time Frame: 2 months ]Detection of any peri-device flow/gap at follow-up cardiac CT/TEE.
- Changes in functional status based on Modified Rankin Scale [ Time Frame: 24 months ]The Modified Rankin scale is used to measure the degree of disability or dependence in daily activities caused by a stroke. The scale runs from 0-6, from no symptoms (0) to death (6).
- Changes in Quality of life [ Time Frame: 12 months ]Based on patient self-reported EuroQol-5D questionnaires. The EuroQol-5D is a standardized instrument to measure health-related quality of life. It includes five self-rated dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The questionnaire have 3 levels of severity for each of the five dimensions. It also includes a visual scale from 0 (worst thinkable health condition) to 100 (best thinkable health condition) to report an overall measure.
- Compliance to NOAC [ Time Frame: 2-, 3-, 5-, and 10-years ]Adherence to assigned NOAC therapy will be assessed through the National Prescription Registries.
- Changes in neurological status based on National Institute of Health (NIH) Stroke scale score [ Time Frame: 12 months ]
Assessed by the NIH stroke scale at baseline and 12 month follow-up. A scale to quantify the neurological impairment caused by a stroke. It includes 11 items, each of which scores a specific ability between 0 to 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores are summed to calculate the total NIH Stroke Scale score, that can range from 0 to 42, with 0 being no symptoms.
- Score 0: No stroke symptoms
- Score 1-4: Minor stroke
- Score 5-15: Moderate stroke
- Score 16-20: Moderate to severe stroke
- Score 21-42: Severe stroke
- Minor bleeding [ Time Frame: 24 months ]Any bleeding clinically mentionable that does not qualify as life-threatening, disabling or major.
- Comparison of the cost-effectiveness of LAAO and NOAC therapy [ Time Frame: 24 months ]All costs and cost-effectiveness will be evaluated and compared between the two diagnostic strategies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03642509
|Contact: Kasper Korsholm, MDemail@example.com|
|Aarhus University Hospital||Recruiting|
|Aarhus, Central Denmark Region, Denmark, 8200|
|Contact: Kasper Korsholm, MD 004578452254 firstname.lastname@example.org|
|Contact: Jens Erik Nielsen-Kudsk, MD DMSc Prof 0078452024 email@example.com|
|Odense University Hospital||Not yet recruiting|
|Odense, Region Of Southern Denmark, Denmark, 5000|
|Contact: Jacob Pontoppidan, MD, PhD|
|Aalborg University Hospital||Recruiting|
|Aalborg, The North Denmark Region, Denmark, 9000|
|Contact: Boris Modrau, MD, PhD|
|Regional Hospital West Jutland||Recruiting|
|Contact: Mohammad Al-Jazi, MD|
|Helsinki University Central Hospital||Recruiting|
|Contact: Juha Sinisalo, MD, PhD|
|Oulu University Hospital||Recruiting|
|Contact: Kari Kervinen, MD|
|Turku University Hospital||Not yet recruiting|
|Turku, Finland, 20521|
|Contact: Juha Lund, MD|
|Haukeland University Hospital||Recruiting|
|Bergen, Norway, 5021|
|Contact: Erik JS Packer, MD|
|Sahlgrenska University Hospital||Recruiting|
|Göteborg, Sweden, 41345|
|Contact: Jacob Odenstedt, MD, PhD|
|Skånes University Hospital||Not yet recruiting|
|Contact: Ole Kongstad|
|Karolinska University Hospital||Not yet recruiting|
|Stockholm, Sweden, 17176|
|Contact: Nikola Drca, MD, PhD|
|Örebro University Hospital||Not yet recruiting|
|Contact: Thomas Kellerth|
|Study Chair:||Kasper Korsholm, MD||Aarhus University Hospital|
|Study Chair:||Jens Erik Nielsen-Kudsk, MD DMSc Prof||Aarhus University Hospital|
|Study Chair:||Dorte Damgaard, MD PhD||Aarhus University Hospital|
|Study Chair:||Søren Paaske Johnsen, MD PhD Prof||Aalborg University Hospital|